Every material Form 8-K Ernexa Therapeutics Inc. has filed with the SEC since September 16, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Ernexa Therapeutics Inc. made an investor presentation available on October 15, 2026, attached as Exhibit 99.1 and posted on its website. The filing is a Regulation FD disclosure and contains no financial results, guidance or deal terms in the text provided, so the filing itself gives shareholders no new financial figures.
Investor presentation made available October 15, 2026, attached as Exhibit 99.1 and posted at investor.ernexatx.com
Filing is furnished under Item 7.01 Regulation FD Disclosure, not filed for Section 18 purposes
Exhibit 99.1 is titled Ernexa Therapeutics Investor Presentation - October 2026; its contents are not included in the filing text provided
Ernexa Therapeutics Inc. made a corporate fact sheet and an investor presentation available on September 16, 2026, attached as Exhibits 99.1 and 99.2 to this Form 8-K. The filing does not disclose financial results, guidance, or other new operating figures in its text, and the company said the materials will also be posted on its website on September 17, 2026.
Corporate fact sheet dated September 16, 2026 filed as Exhibit 99.1
Investor presentation dated September 2026 filed as Exhibit 99.2
Materials to be posted at investor.ernexatx.com on September 17, 2026
Information is furnished under Item 7.01, not filed, under the Exchange Act
Ernexa Therapeutics appointed Robert J. Spiegel, M.D. as a member of its board of directors, effective immediately, on the recommendation of the Nominating and Corporate Governance Committee. The filing says he will be compensated under the company's board compensation plan and reports no related-party transactions or family relationships with other directors or executives.
Board appointment approved September 14, 2026; effective immediately
Dr. Spiegel's compensation follows the Board of Directors Compensation Plan adopted effective August 15, 2026
Filing reports no reportable transactions with Dr. Spiegel under Item 404(a) of Regulation S-K
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Ernexa Therapeutics Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →